Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
manibiotech,
First you need to get the market’s attention again. After all these years of product development and price manipulation because of the time factor involved they aren’t looking in this direction when they should be because the time factor is now coming much more clearly into focus. We received the early look because we are paying attention. The learning curve is now in progress which is why the bears are going to have trouble holding this down now. Any longs that had reservations about the timing and ability to rapidly advance are now in the process of seeing those concerns alleviated. Those who got burned before by price manipulation can now be shown a conditional time frame for justice to be rendered and the reason why their original investment was sound even if fear got the best of them because they allowed themselves to be played by crooks.
I sure would like to see a courtroom full of financial victims and cancer patients watching the jury hand down their decision about monetary award to NWBO with the DOJ reps in the room to bring the criminal charges before they even step out of the court room. Now that would be the beginning of justice. Best wishes.
Smitty5150,
We may disagree about timing and price of buyout but you are a perfect example of the point I have been making about the Eden’s update which is that Edens is a value driver because of known scalability. This announcement also gives us a likely starting point for combo trial announcements and partnership(s) which can be value drivers, especially partnership. Best wishes.
Horseb4CarT,
I don’t know about that. I once heard a joke about a plane going down with only the pilot, a pastor, a Boy Scout and the smartest person in the world on board and only 3 parachutes. The smartest guy in the world got his pack quickly and made the jump first thinking it best to have the most altitude to work with. The pilot then informed the other two that they should go and that he would stay behind. The Boy Scout quickly responded that there was no need for that since the smart guy had just jumped out with his back pack on ; ). Hope there are no real longs ready to do the same when the plane the bears are in, that they try to convince we are in, is ready to go down in flames. Best wishes.
dealerschool2006,
Automation with GMP certification in a few months, approval and a scale up model with fewer product release hurdles in the US than in the UK or EU staring at them at about the same time. You tell me when you think the market will “wise up” to the fact that combo trials and partnership have been waiting on this. I’d say if longs can’t figure out what they need to do to suck it up and finish over the next several months before the price bounces into the upper trend zone they never will. The bears really have their work cut out for them now. Best wishes.
evenstony,
Now is not the time for a buyout at those numbers when in three years or less from approval the number would be easily $50 or more and annual growth rate of above100% . Makes no sense. Linda knows much better than us when the right time to sell will be and she has already stated this which the Danish Dude revisited recently. Best wishes.
BlackMountain,
The NWBO shares granted with the purchase of Flaskworks will be worth quite a bit some day so maybe not a complete steal. The fact that Northeastern University and Dr. Shashi Murthy were contacted by NWBO to develop this tech before Corning helped manufacture the initial prototypes really does not make this a complete steal either but rather a very opportunistic purchase for NWBO and its investors. The unknown wait time Corning and other contributors were going to need to endure before revenues could be generated was likely a big consideration for them too. Best wishes.
flipper44,
Guess I had a pretty timely post yesterday and today’s new plus approval and final GMP validation will open the doors for everything else for and with a partnership announcement. The bounce to the upper trend lines is now being firmly established as likely in Q3-Q4 of this year ; ). Best wishes.
flipper44,
No hand wringing, just waiting for the surprise. When NWBO gets quiet about stuff they have been talking about something big is usually in the works. By the way, I agree that getting L across the line and submitted with potentially just the artisan method is a big deal and gives cancer patients hope for a pathway forward to a cure in GBM, rGBM and other lower grade gliomas as well as other solid tumor cancers in time. I just think the demand will come fast and furious for use of this tech in all solid tumor cancers once folks realize how this platform works and that requires being ready for. Best wishes.
dennisdave,
Dr. Bosch and Alton Boynton both did research on L and Direct and continue. There is also a lab in Maryland or at least used to be there and there is always ongoing patent research by NWBO employees. The SAB is also hired as payed advisors and they are all researchers. Best wishes.
flipper44,
I was thinking something along the same lines. Seems the thinking might be that care after progression is not cost effective. Best wishes.
flipper44,
The 5 year survival tail is supposed to be ~5% even with SOC but in this trial neither treatment arm or SOC had any 5 year survivors even with separation noted. Really strange in that regard but also in line with what some doctors have stated that until DCVax and Optune they had never seen a 5 year survivor in their clinical practice. Best wishes.
flipper44,
I agree that to Linda an update about Edens might have seemed like a distraction before the MAA application was submitted. However this is a key point of interest to investors as one of the last big runs was based on manufacting expectations with the acquisition of Flaskworks. Dr. Bosch also gave an update on manufacturing at the industry expert theater presentation in 2022 then Linda commented in December of that year at the ASM. Seems to me they were setting up expectations for additional updates which have not come. This gave additional ammo to bears and they have used this and delays to submission to their advantage.
The value driver for this treatment is not only the ability to lead towards a cure but also the ability to reach the masses and contol costs sooner rather than later. This is what Edens represents. When analysts and investors see bottlenecks they see limits in value. When bottlenecks disappear they see rising value. If this is all part of the MAA package then the market gets a big surprise and so do the shorts. Best wishes.
eagle8,
Just some minor corrections. The price before the advisory committee decision was announced was a little over $5 and ended the first day at near $12.50 which ended up being a one day 150% gain and by the time of the settlement date a few days later the price had gone as high as ~$25 . The legal short position was over 25% which had much to do with this. The legal short position for NWBO is no where near that level and is not expected to ever be. The fun begins when longs get their shares locked up tight before an MHRA decision is announced and if NWBO lines up supporting news to catapult the stock before the markets open then those that have shares on the offer cheap will have time to remove them before the open and create a premarket scramble on the bid as those cheap offers get removed and longer standing higher offers take the stage front and center before the opening bell.
With DNDN the premarket bids were at over $18 and dropped down to $17 and change at the open. Like I said before the close was close to $12.50 and a 150% gain so longs can take a lesson about volatility from reviewing this action. If manipulators think they can hold the price below $5 by shorting, spoofing or other they will try in my opinion. If a partnership is announced that makes this impossible they will cover at the lowest price they can to avoid institutional and or Reddit like involvement. This means that NWBO strategy is key to how this plays out when this time they have the ability to hold the upper hand especially if the court decides that accused spoofers ought to be kept from making a market in NWBO because of court document admission that they do so. Best wishes.
Inquirig,
I’ll play nice. So let’s start out by you saying you were going to put me on ignore; ). Then let’s look at your claim that NWBO share price will go to zero. Everyone who has been on this board for any length of time knows that IP value alone places this stock considerably above zero. Even if you could possibly find a way to ignore the JAMA Oncology validated conclusions based on ECAs which you can’t because only regulator opinion matters and they green lighted the PIP with the same methodology, BP research alone validated dendritic cell treatments as combo enhancers of their own checkpoint inhibitors by a very significant percentage years ago. This is now currently backed by the early UCLA combo data so no, this stock price is not going to zero as much as any manipulator would want it to which means your claim/opinion is knowingly false which makes it a lie disguised as an opinion. Too late for that “opinion” to hold any water!; ). There are others but let’s start with simple. Best wishes.
Poor Man -,
Maybe the jury award will make you feel better about the way the share price has been manipulated but you’ll need to wait a bit longer for that ; ). Best wishes.
flipper44,
True about the page change but no one knew for sure if it was a pre planned addition ready to go or not. I was under the assumption it was, had been running parallel and was ready. Obviously it was not and the bears likely knew or were going to challenge by assumption that it was not and we never received an update on Edens which I expected by last June from Dr. Bosch. Best wishes.
meirluc,
The issue is the flow of positive news events. Obviously a partnership deal announced near or at the time of approval would make any attempt to manipulate very difficult to impossible. Approval without this news needs to be followed up with positive statements by the company about how they expect to bring income into the picture without delay. That requires them to project how much revenue will be available from immediately available UK set asides and or bring a NICE decision time line into play. They must also project what growth rate they expect based on initial expected demand from all comers and new trial plans and financing plan for them if an outright partnership is not announced. They can project a modest initial growth rate but need to project a strong build. I believe Linda has post approval moves covered but if not done properly this is where manipulation could continue after an initial surge.
I believe there is a very significant amount of news that can and will be shared that will help ward off manipulation after approval but if any opening is left for it you can be certain that opening will be taken especially if any hostile buyout offers are brought into the mix. Best wishes.
Inquirig,
Well based on the responses you received your opinion about NWBO does not seem to be worth very much.
Let’s put it to the test:
On a scale from 0-10 how much is Inquirig’s OPINION about NWBO worth?; ).
PS this is not an opinion scale about the value of Inquirig. We all know in God’s eyes she is of such great worth as to be priceless. Best wishes.
LessIsMore,
$.54 represents a 10% discount to the base line uptrend. They got it to ~$.53 now letting it bounce. Let’s see what next week brings with regard to buying interest. Good accumulation set up. Best wishes.
NOTBOB17,
Cramer knows about NWBO. He commented on them years ago. He is just holding up the status quo that he works with… until their allegiances shift. Best wishes.
vator,
I think the compensation is tied more to actual progress instead of manipulated share price. Kind of boggles the mind to think that all the data available indicates not only a positive outcome in the Phase 3 trial but many advances being seen outside of this trial and ready to be implemented almost immediately upon approval so that patients benefit way more than what trial results demonstrated. I am more than willing to wait in line so that patients know they are the ones who will have access to this treatment first twitch rewards to investors following. This includes Linda Powers who has much more to gain with her shares than any compensation from all sources seen up until the point she chooses to sell. Best wishes.
flipper44,
Dr. Ashkan holds considerable sway concerning best practices for any neurosurgery in the UK. I wonder if there is anything written in guidelines by now regarding this or if this is just word of mouth. Best wishes.
flipper44,
There were some big block trades going on indicating some potential accumulation back then but then there was a change in wording from 1 million pages to 1.7 million pages if you recall. That obviously ended up creating a change in timeline and also a likely change in accumulation strategy which led to last summer’s price melt down. This makes complete sense if there was a side by side submission strategy going on and Edens finally was ready or nearly ready to be placed into the submission as well as the proteomics data that strengthens the case for tissue agnostic designation that we were made aware of. The juggling and perhaps expected potential breakthrough with Edens would have been happening all during this time. I was expecting an announcement about Edens after almost a year without any definitive news back then and expected that would heat up speculation about a partnership or CRL announcement. I think those that were anccumulating were thinking along the same lines. I also think some big investors got anxious enough to sign an NDA during this time and li and behold, none of them are saying much of anything anymore.
Anything that gives Wall Street and investors reason to believe that revenue is on the way from expected approval would provide a big boost. Partnerships tend to solidify that expectation. That never happened timely last year and now it seems no one is going to say anything before approval even if payments for milestones get reported in a 10Q. Perhaps Merck or someone else NWBO is dealing with wants it this way for strategic reasons. I think we all understand why that may be even if we need to be put through the manipulation grinder until news because of this. Lots of moving parts that everyone seems to be very quiet about, not just NWBO. If this is all happening and a few big vocal supporters signed NDAs just to prevent a sell off by them then it goes a long way to explain the current lack of price support. Best wishes.
exwannabe,
Key word “collaboration”. Key example “Daiichi Sankyo” maker of a product expected to be tested in combo with keytruda and murcidencel (DCVax-L). Key take away, likely no buyout of NWBO yet by Merck but collaboration not out of the question and potentially being very indirectly pointed to. Maybe all the building going on in Pennsylvania should have been asked about by dstock; ). I would love to see the body language seen to that question being tied to NWBO. Best wishes.
flipper44,
Yep and I said that upper trend range is still in play this year. There were some big trades being made then but we all saw the delays at getting the app in likely because of Edens and or proteomics info they wanted added in. So everything got pushed back. That includes partnership plans with it which I expect to be the driving force for initial upper trend price support. Like I have said for the last two years or so, time is the only real risk because the data had been expected to be good for quite some time. Best wishes.
flipper44,
The collaboration you speak of is exactly what you need to instantly bring the price up to a higher buyout level. Anything is theoretically possible but extracting max value before a buyout almost always takes some time and Linda said this at an ASM years ago.
The upper trend baseline sits above $12 and as I said, I believe we can be there by the end of Q3 if not before. So does a buyout now at $12 (~23X) seem better than a collaboration at a percentage of shares at $12 or other equivalent and buyout later? What is happening now is what happens in biotech and Sojourner55 showed the chart and I also warned that this is what the bears can often do during quiet periods like this before an approval decision. It’s their last best opportunity and ends in major reversals for stocks expected to get positive news. What I didn’t know is if longs would start making a significant defense near $.55 or just let the price drop. With 45,000 longs buying an average of 2000 shares a month at these levels until approval the daily volume would be more than completely covered. So where is the support?
Longs are demonstrating that they are worn out and tapped out which is exactly where the manipulators want them. What happens to the price between now and approval should be considered just part of getting to greener pastures after approval because of how manipulation and dilution are being worked hand in hand. In the mean time longs need to figure out how they are going to finish by either just waiting or proactively buying because that is exactly what traders and manipulators will be doing at some point when they finally decide to cover shorts and take long positions which is when there will be a radical turn around that I told you could happen apparently out of the blue as manipulators switch their bets in anticipation of approval which then gets pushed on the message boards and emotional buying comes back into the picture.
Just because I have seen this stuff play out before does not mean I can control how it plays out. I can only control how I act on it or react to it which is what I try to get other longs to understand who haven’t been through all of this before. Let’s finish strong!; ). Best wishes.
FeMike,
You aren’t saying anything different here than what skitahoe and a few others have been saying for quite some time. You just take a constant pounding because you get too negative sometimes; ). I’ve been getting more lately too because it comes with the territory we are in now. Expectations and tensions are high as we wait and those of us who see and know there is value must be patient for it to appear while others work to convince it’s not there and are working the price down to buy from traders cheaply on the way back up. Best wishes.
flipper44,
What FeMike is saying is that the right information and the right amount of time can get to what you are talking about but that we must first bridge that gap. The debate being created here is really more about how much time is needed to prove that potential with approvals or revenues and whether or not NWBO can be forced into an unwanted buyout situation at undervalued prices compared to underlying intrinsic value of the platform before then.
I believe much will be revealed once L is approved but that the magnitude of what they are capable of doing will take about 3 years to fully sink in from trials and data from them started later this year and next. Let’s just wait for “the right kind of news” that propels us into the upper trend range by end of Q3 this year as spec value comes into play. Best wishes.
vator,
Now you see a little bit why the wait is worth it and why low valuations for early buyout would be foolish for Linda to even consider when just a little more waiting brings the validation needed for platform value. I understand why many don’t see this now but I think many of the big longs are or have figured this out. Best wishes.
hyperopia,
Retail interest has been tamped down because of past bear raids so the interim news cycles mean very little to current longs and new investors because they can all see the lack of sustained buying afterwards and drop in price that you show clearly in your post and which biosectinvestor believes is likely to continue even after approval if there are no strong counter measures able to be put in place. The approval process is also hurting investors because no clear plan forward has been reiterated. Linda is on record as saying that NWBO would manage GBM but that was quite some time ago. With ongoing dilution, fear of bear raids, longs in up to the gills, no trust by those burned in the past that potential shortened time lines to expectation of approval are real and of course the extra manipulation to press downward price movement faster than actual dilution have all eroded confidence about timing when a gain will be locked in with a purchase of shares. Waterboarding the long term uptrend baseline is the method used currently to intensify this uncertainty for potential buyers.
Bottom line is that manipulation is made easier by uncertainty, known need for additional dilution and any extended time without the right kind of news which makes quiet periods easy targets even when good news is eventually expected. The lawsuit developments may allow a significant countermeasure to be put in place and we know partnership news would do this as well. Best wishes.
Mico1,
Just par for the course as NWBO needs to sell shares until news and traders are taking advantage. Some longs are buying at a pace that keeps the price from falling faster and harder while we wait but only some good news will turn this around. Longs apparently aren’t inspired at these levels to buy at a quicker pace until expected news based on today’s action. Looks like longs are mostly only prepared to wait out the news while the price drops from manipulation and known sales of shares by NWBO in the interim. The pace of dilution is far less than the pace of price decrease over the last month or so which indicates manipulation is in play and is offering opportunity to be taken advantage of. A post from skitahoe indicates he may be doing so shortly and FeMike indicated he would as well. I know someone who bought more today as well and I have an order pending. Hoping it acts as a placeholder to keep manipulators from moving the price lower cheaply and doesn’t get filled. If it does, fewer for them to work with next time. Best wishes.
manibiotech,
Retail is not the only group that sees the writing on the wall. There are some big unhindered investors that will want a stake in this by May/June sometime even if March turns out not to be a surprise month for news. It’s up to current longs and traders to set the floor in the mean time. Best wishes.
manibiotech,
Bottom line is we are below the long term $.01/month uptrend started in March/April 2020 by the market makers in a waterboarding situation not unlike last summer. The price is expected to bounce out of this and approval plus any partnership agreement puts us right into the upper trend zone above $12 pretty quickly. I understand the fixation by some on absolutes with regard to GBM, rGBM only but that simply is not going to happen in this case in my opinion. Way too much news to share that points to much wider use more quickly than before because this is going to be recognized widely as a breakthrough platform by investors and more importantly, clinicians working to save their patients. Best wishes.
manibiotech,
Go look at the chart he showed. There is room for it to drop further but the buy zone is clear because it will bounce out of this zone higher in a typical rebound scenario when the news comes. Getting absolute bottom with volume buying is almost never possible so buying is done along the way down starting when the buy zone appears or a little later depending on the volume desired out of the volume being traded. You know the game being played by market makers and traders. Best wishes.
manibiotech,
He did not predict a bottom here. He showed where buying might be expected to be coming in. Best wishes.
flipper44,
Changes can happen very suddenly to the upside at this place in development cycle. There is likely and more likely timing for this to happen but many of the things you have been posting about are considerations in the timing of moves by certain investors and there are likely plenty of moving parts for all to consider with regard to future trials, partners etc. Linda likely has a time zero plan to implement one strategy or another which will determine the value proposition going forward. Until that time comes some will try to work the clock and stock price believing they know her options and potential timing and can control the price. The next few days will shed some light into how confident they are about timing of events by the way the stock price reacts. Best wishes.
RobotDroid,
You all make me laugh. Bottom of a cycle, waiting for great news, longs holding strong, some ready to buy more and you agree with Inquirig after price bounces off of $.55 as predicted possible. All you are doing is reinforcing the buy signal Sojourner55 was pointing to in the charts with one of his recent posts. Thanks for the contrarian indicator; ). Best wishes.
meirluc,
My thinking as well since I believe they were far enough along to be preparing side by side applications for presentation with or without Edens. This would also warrant “an investment” by Merck and or other(s) without a contractual agreement in writing as a good faith measure similar to NWBO needing to have manufacturing in place before approval from MHRA. Best wishes.
iclight,
Read your original post. You missed the point that Linda will be helping some longs to buy the yachts they have talked about. Best wishes.
flipper44,
Looks possible but not banking on it. Sure would love to see the surprise though and talk about embarrassment for FDA. Imagine what this could mean for Direct too. Best wishes.